Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer

Bibliography

• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012;490:61-70
   PubMed Web of Science ®Google Scholar
• LAMartin, FAndré, MCampone, et al. mTOR inhibitors in advanced breast cancer: ready for prime time? Cancer Treat Rev 2013;39:742-52
   PubMed Web of Science ®Google Scholar
• ECiruelos, HCortes-Funes, IGhanem, et al. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs 2013;24:769-80
   PubMed Web of Science ®Google Scholar
• DAFruman, CRommel. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56
   PubMed Web of Science ®Google Scholar
• RSchiff, SAMassarweh, JShou, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-6S
   PubMed Web of Science ®Google Scholar
• LRYalnik, ADigilova, DCDavis, et al. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009;284:6361-9
   PubMed Web of Science ®Google Scholar
• KBerns, HMHorlings, BTHennessy, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402
   PubMed Web of Science ®Google Scholar
• GIKirchner, IMeyer-Wiedenbach, MPMannus. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95
   PubMed Web of Science ®Google Scholar
• JMKovarik, SHartmann, JFigueiredo, et al. Effect of food on everolimus absorption: quantification in healthy subjects and confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9
   PubMed Web of Science ®Google Scholar
• JPeveling-Oberhag, SZeuzem, WPYong, et al. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin Ther 2013;35:215-25
   PubMed Web of Science ®Google Scholar
• ABoulay, SZumstein-Merker, CStephan, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivate RAD001correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61
   PubMed Web of Science ®Google Scholar
• CTanaka, TO’Reilly, JMKovarik, et al. Identifying optimal biologic doses of everolimus (RAD001)in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamics data. J Clin Oncol 2008;26:1596-602
   PubMedGoogle Scholar
• AO’Donnel, SFaivre, HABurrisIII, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients in advanced solid tumors. J Clin Oncol 2008;26:1588-95
   PubMed Web of Science ®Google Scholar
• JTabernero, FRojo, ECalvo, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10
   PubMed Web of Science ®Google Scholar
• AAwada, FCardoso, CFontaine, et al. The oral mTOR inhibitor RAD. 001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91
   PubMed Web of Science ®Google Scholar
• JBaselga, VSemiglazov, Pvan Dam, et al. Phase II randomized study of neaoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients in estrogen receptor-pozitive breast cancer. J Clin Oncol 2009;27:2630-7
   PubMed Web of Science ®Google Scholar
• TBachelot, CBourgier, CCropet, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30:2718-24
   PubMed Web of Science ®Google Scholar
• ITreilleux, MArnedos, CCropet, et al. Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): Final results of the TAMRAD trial translational study. J Clin Oncol 2013;31(Suppl):abstract 510
   Google Scholar
• SLoi, SMichiels, JBaselga, et al. PIK3CA genotype and PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. Plos One 2013;8:e53292
   Google Scholar
• DAYardley, SNoguchi, KIPritchard, et al. Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO 2 final progression-free survival analysis. Adv Ther 2013;30:870-84
   PubMed Web of Science ®Google Scholar
• MPiccart, GNHortobagyi, MCampone, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breaset cancer: overall survival results from BOLERO-2. Ann Oncol 2014;25(12):2357-62
   PubMed Web of Science ®Google Scholar
• GNHortobagyi, MJPiccart-Gebhart, HRugo, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2013;31(Suppl):abstract LBA509
   Google Scholar
• PKMorrow, GMWulf, JEnsor, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed in trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32
   PubMed Web of Science ®Google Scholar
• GBernadou, KRezai, JLMerlin, et al. Trastuzumab (T) and everolimus (E) pharmacokinetics in HER2 positive primary breast cancer (BC) patients (pts): unicancer RADHER trial results. J Clin Oncol 2013;31(Suppl):abstract 2599
   Google Scholar
• FAndré, MCampone, RO’Regan, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;34:5110-15
   Google Scholar
• GJerusalem, AFasolo, VDieras, et al. Phase I trial of oral mTOR inhibitor everolimus in combonation with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011;125:447-55
   PubMed Web of Science ®Google Scholar
• RO’Regan, MOzguroglu, FAndre, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013;31(Suppl):abstract 505
   Google Scholar
• FAndré, RO’Regan, MOzguroglu, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomized, double-blind, placebo controlled phase 3 trial. Lancet Oncol 2014;15:580-91
   PubMed Web of Science ®Google Scholar
• GJerusalem, FAndré, DChen, et al. Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trail. Eur J Cancer 2013;49(Suppl 3):PS8
   Google Scholar
• SAHurwitz, FAndré, HABurris, et al. BOLERO-1: a randomized, phase III, double-blind, placebo controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel in first-line therapy in women with HR2-positive (HER2+), locally advanced or metastatic breast cancer (BC). J Clin Oncol 2012;30(Suppl):abstract TPS648
   Google Scholar
• US National Institutes of Health. Trastuzumab with or without everolimus in treating women with breast cancer that can be removed by surgery. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00674414?term =NCT00674414&rank=1 [Accessed 17 May 2014]
   Google Scholar
• DNFranz, EBelousova, SSparagana, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a milticentre, randomized, placebo controlled phase 3 trial. Lancet 2013;381(9861):125-32
   PubMed Web of Science ®Google Scholar
• A study of everolimus, trastuzumab and vinorelbine in HER2-positive breast cancer brain metastases. Available from: https://clinicaltrials.gov/ct2/results?term=NCT+01305941+ [Accessed 12 January 2015]
   Google Scholar
• Phase 1b/2 trial using lapatinib, everolimus and capecitabine for treatment of HER-2 positive breat cancer with CNS metastasis. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01783756+ NCT01783756 [Accessed 12 January 2015]
   Google Scholar
• RDent, MTrudeau, KIPritchard, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34
   PubMed Web of Science ®Google Scholar
• IMayer, HBurris, JBendell, et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2009;69(24 Suppl):abstract 3093
   Google Scholar
• JCSingh, YNovik, SStein, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014;16:R32
   PubMed Web of Science ®Google Scholar
• NECTAR everolimus plus cisplatin in triple (-) breat cancer. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01931163 [Accessed 12 January 2015]
   Google Scholar
• IAMayer, JMeans-Powell, YShyr, et al. A phase Ib trail of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor in patients with metastatic breast cancer [abstract 254]. 32nd Annual San Antonio Breast Cancer Symposium; 9 – 13 December 2009; San Antonio, Texas
   Google Scholar
• SChan, MEScheulen, SJonhnston, et al. Phase II study of temsirolimus (CCI-779) -, a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22
   PubMed Web of Science ®Google Scholar
• ACWolff, AALazar, IBondarenko, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202
   PubMed Web of Science ®Google Scholar
• SBanerji, KCibulskisn, CRangel-Escarceno, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;482:405-9
   PubMedGoogle Scholar
• JMEllis, LDing, DShen, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60
   PubMed Web of Science ®Google Scholar
• PJStephens, PSTarpey, HDavies, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4
   PubMed Web of Science ®Google Scholar
• SNik-Zainal, PVan Loo, DCWedge. The life history of 21 breast cancers. Cell 2012;149:994-1007
   PubMed Web of Science ®Google Scholar
• CDesmedt, DBrown, BSzekely, et al. Unraveling breast cancer progression through geographical and temporal sequencing [abstract nr 986]. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 5 – 9 April 2014; San Diego, CA. Philadelphia
   Google Scholar
• VAlmendro, KHee Jung, CYu-Kang, et al. Genetic and phenotypic diversity in breast cancer metastases. Cancer Res 2014;74:1338-48
   PubMed Web of Science ®Google Scholar
• Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor positive and HER2-neu negative breast cancer: NCT01674140. Available from: http://clinicaltrials.gov/ct2/show/NCT01674140 [Accessed 24 May 2014]
   Google Scholar
• Randomized, double blind, multicentric phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving 3 years of adjuvant hormone therapy: NCT01805271. Available from: http://clinicaltrials.gov/ct2/show/NCT01805271?term=UNIRAD&rank=1 [Accessed 24 May 2014]
   Google Scholar
• GIyer, AJHanrahan, MIMilowsky, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221
   PubMed Web of Science ®Google Scholar
• MElkabets, SVora, DJuric, et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013;5:196-9
   Google Scholar
• SAWander, BTHennessy, JMSlingerland. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41
   PubMed Web of Science ®Google Scholar
• DBenjamin, MColombi, CMoroni, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10:868-80
   PubMed Web of Science ®Google Scholar
• MRJanes, DAFruman. Targeting TOR dependence in cancer. Oncotarget 2010;1:69-76
   Google Scholar
• A Phase IIIB, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with exemestane: 4EVER - efficacy, safety, health economics, translational research : NCT01626222. Available from: http://clinicaltrials.gov/show/NCT01626222 [Accessed 25 May 2014]
   Google Scholar